Clinical Trial Update: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating mosunetuzumab plus lenalidomide versus anti-CD20 antibody plus chemotherapy in follicular lymphoma (FLIPI2-5) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Mosunetuzumab (mosunetuzumab)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Follicular Lymphoma | Phase 3 | Status: RECRUITING